journal
https://read.qxmd.com/read/37708901/current-insights-and-emerging-trends-in-early-onset-type-2-diabetes
#1
REVIEW
Shivani Misra, Calvin Ke, Shylaja Srinivasan, Alpesh Goyal, Moffat J Nyriyenda, Jose C Florez, Kamlesh Khunti, Dianna J Magliano, Andrea Luk
Type 2 diabetes diagnosed in childhood or early adulthood is termed early-onset type 2 diabetes. Cases of early-onset type 2 diabetes are increasing rapidly globally, alongside rising obesity. Compared with a diagnosis later in life, an earlier-onset diagnosis carries an unexplained excess risk of microvascular complications, adverse cardiovascular outcomes, and earlier death. Women with early-onset type 2 diabetes also have a higher risk of adverse pregnancy outcomes. The high burden of complications renders individuals with early-onset type 2 diabetes at future risk of multimorbidity and interventions to reverse these concerning trends should be a priority...
September 11, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37708900/life-expectancy-associated-with-different-ages-at-diagnosis-of-type-2-diabetes-in-high-income-countries-23-million-person-years-of-observation
#2
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: The prevalence of type 2 diabetes is increasing rapidly, particularly among younger age groups. Estimates suggest that people with diabetes die, on average, 6 years earlier than people without diabetes. We aimed to provide reliable estimates of the associations between age at diagnosis of diabetes and all-cause mortality, cause-specific mortality, and reductions in life expectancy. METHODS: For this observational study, we conducted a combined analysis of individual-participant data from 19 high-income countries using two large-scale data sources: the Emerging Risk Factors Collaboration (96 cohorts, median baseline years 1961-2007, median latest follow-up years 1980-2013) and the UK Biobank (median baseline year 2006, median latest follow-up year 2020)...
September 11, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37708899/many-years-of-life-lost-to-young-onset-type-2-diabetes
#3
JOURNAL ARTICLE
Bruce B Duncan, Maria Inês Schmidt
No abstract text is available yet for this article.
September 11, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37696274/is-it-time-to-re-assess-the-development-of-thyroid-function-reference-ranges
#4
JOURNAL ARTICLE
Elizabeth N Pearce
No abstract text is available yet for this article.
September 8, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37696273/the-optimal-healthy-ranges-of-thyroid-function-defined-by-the-risk-of-cardiovascular-disease-and-mortality-systematic-review-and-individual-participant-data-meta-analysis
#5
JOURNAL ARTICLE
Yanning Xu, Arash Derakhshan, Ola Hysaj, Lea Wildisen, Till Ittermann, Alessandro Pingitore, Nazanin Abolhassani, Marco Medici, Lambertus A L M Kiemeney, Niels P Riksen, Robin P F Dullaart, Stella Trompet, Marcus Dörr, Suzanne J Brown, Börge Schmidt, Dagmar Führer-Sakel, Mark P J Vanderpump, Axel Muendlein, Heinz Drexel, Howard A Fink, M Kamran Ikram, Maryam Kavousi, Connie M Rhee, Isabela M Bensenor, Fereidoun Azizi, Graeme J Hankey, Massimo Iacoviello, Misa Imaizumi, Graziano Ceresini, Luigi Ferrucci, José A Sgarbi, Douglas C Bauer, Nick Wareham, Kristien Boelaert, Stephan J L Bakker, J Wouter Jukema, Bert Vaes, Giorgio Iervasi, Bu B Yeap, Rudi G J Westendorp, Tim I M Korevaar, Henry Völzke, Salman Razvi, Jacobijn Gussekloo, John P Walsh, Anne R Cappola, Nicolas Rodondi, Robin P Peeters, Layal Chaker
BACKGROUND: Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4 ) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease and mortality. METHODS: This systematic review and individual participant data (IPD) meta-analysis identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a systematic search via Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from Jan 1, 2011, to Feb 12, 2017 with an updated search to Oct 13, 2022 (cohorts found in the second search were not included in the IPD)...
September 8, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37683679/craniopharyngioma-medico-social-support-for-optimised-care
#6
LETTER
Thomas Cuny, Rachel Reynaud, Pascal Barat, Blandine Gatta-Cherifi
No abstract text is available yet for this article.
September 5, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37666263/maternal-type-1-diabetes-and-relative-protection-against-offspring-transmission
#7
REVIEW
Lowri A Allen, Peter N Taylor, Kathleen M Gillespie, Richard A Oram, Colin M Dayan
Type 1 diabetes is around twice as common in the offspring of men with type 1 diabetes than in the offspring of women with type 1 diabetes, but the reasons for this difference are unclear. This Review summarises the evidence on the rate of transmission of type 1 diabetes to the offspring of affected fathers compared with affected mothers. The findings of nine major studies are presented, describing the magnitude of the effect observed and the relative strengths and weaknesses of these studies. This Review also explores possible underlying mechanisms for this effect, such as genetic mechanisms (eg, the selective loss of fetuses with high-risk genes in mothers with type 1 diabetes, preferential transmission of susceptibility genes from fathers, and parent-of-origin effects influencing gene expression), environmental exposures (eg, exposure to maternal hyperglycaemia, exogenous insulin exposure, and transplacental antibody transfer), and maternal microchimerism...
September 1, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37660720/the-traverse-trial-cardiovascular-safety-of-testosterone-therapy-for-older-men
#8
JOURNAL ARTICLE
Bradley D Anawalt
No abstract text is available yet for this article.
August 31, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37652072/call-for-prospective-studies-of-continuous-glucose-monitoring-to-define-the-glycaemic-response-to-bariatric-surgery
#9
JOURNAL ARTICLE
Lia Bally, Bernard Khoo, Filip Knop, Sten Madsbad, Mary-Elizabeth Patti, Tricia Tan
No abstract text is available yet for this article.
August 28, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37619580/good-news-for-patients-with-adrenocortical-carcinoma-from-the-adiuvo-trial
#10
JOURNAL ARTICLE
Martin Reincke
No abstract text is available yet for this article.
August 21, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37619579/adjuvant-mitotane-versus-surveillance-in-low-grade-localised-adrenocortical-carcinoma-adiuvo-an-international-multicentre-open-label-randomised-phase-3-trial-and-observational-study
#11
JOURNAL ARTICLE
Massimo Terzolo, Martin Fassnacht, Paola Perotti, Rossella Libé, Darko Kastelan, André Lacroix, Wiebke Arlt, Harm Reinout Haak, Paola Loli, Bénédicte Decoudier, Helene Lasolle, Marcus Quinkler, Magalie Haissaguerre, Olivier Chabre, Philippe Caron, Antonio Stigliano, Roberta Giordano, Maria Chiara Zatelli, Irina Bancos, Maria Candida Barisson Villares Fragoso, Letizia Canu, Michaela Luconi, Soraya Puglisi, Vittoria Basile, Giuseppe Reimondo, Matthias Kroiss, Felix Megerle, Stefanie Hahner, Otilia Kimpel, Tina Dusek, Svenja Nölting, Isabelle Bourdeau, Vasileios Chortis, Madeleine Hester Ettaieb, Deborah Cosentini, Salvatore Grisanti, Eric Baudin, Paola Berchialla, Francesca Bovis, Maria Pia Sormani, Paolo Bruzzi, Felix Beuschlein, Jerome Bertherat, Alfredo Berruti
BACKGROUND: Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk of recurrence. METHODS: ADIUVO was a multicentre, open-label, parallel, randomised, phase 3 trial done in 23 centres across seven countries...
August 21, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37562425/correction-to-lancet-diabetes-endocrinol-2023-11-490-508
#12
(no author information available yet)
No abstract text is available yet for this article.
August 7, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37549682/national-uk-guidelines-for-the-management-of-paediatric-craniopharyngioma
#13
REVIEW
Hoong-Wei Gan, Paul Morillon, Assunta Albanese, Kristian Aquilina, Chris Chandler, Yen-Ching Chang, Evangelos Drimtzias, Sarah Farndon, Thomas S Jacques, Márta Korbonits, Adam Kuczynski, Jennifer Limond, Louise Robinson, Ian Simmons, Nick Thomas, Sophie Thomas, Nicola Thorp, Faraneh Vargha-Khadem, Daniel Warren, Bassel Zebian, Conor Mallucci, Helen Alexandra Spoudeas
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To date, the optimal management strategy for these tumours remains undefined, with practice varying between centres...
August 4, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37536357/achieving-replicable-subphenotypes-of-adult-onset-diabetes-authors-reply
#14
LETTER
Norbert Stefan, Matthias B Schulze
No abstract text is available yet for this article.
July 31, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37536356/achieving-replicable-subphenotypes-of-adult-onset-diabetes
#15
LETTER
Jithin Sam Varghese, Rodrigo M Carrillo-Larco, Km Venkat Narayan
No abstract text is available yet for this article.
July 31, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37524103/mechanisms-and-clinical-relevance-of-the-bidirectional-relationship-of-viral-infections-with-metabolic-diseases
#16
REVIEW
Nikolaos Perakakis, Hani Harb, Benjamin G Hale, Zsuzsanna Varga, Charlotte Steenblock, Waldemar Kanczkowski, Vasileia Ismini Alexaki, Barbara Ludwig, Peter Mirtschink, Michele Solimena, Nicole Toepfner, Sebastian Zeissig, Manuel Gado, Irene Alma Abela, Felix Beuschlein, Giatgen A Spinas, Claudia Cavelti-Weder, Philipp A Gerber, Michael Huber, Alexandra Trkola, Milo A Puhan, Wendy Wei-Lynn Wong, Andreas Linkermann, Viswanathan Mohan, Hendrik Lehnert, Peter Nawroth, Triantafyllos Chavakis, Geltrude Mingrone, Christian Wolfrum, Annelies S Zinkernagel, Stefan R Bornstein
Viruses have been present during all evolutionary steps on earth and have had a major effect on human history. Viral infections are still among the leading causes of death. Another public health concern is the increase of non-communicable metabolic diseases in the last four decades. In this Review, we revisit the scientific evidence supporting the presence of a strong bidirectional feedback loop between several viral infections and metabolic diseases. We discuss how viruses might lead to the development or progression of metabolic diseases and conversely, how metabolic diseases might increase the severity of a viral infection...
July 28, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37499675/comparative-effectiveness-of-sglt2-inhibitors-glp-1-receptor-agonists-dpp-4-inhibitors-and-sulfonylureas-on-risk-of-major-adverse-cardiovascular-events-emulation-of-a-randomised-target-trial-using-electronic-health-records
#17
JOURNAL ARTICLE
Yan Xie, Benjamin Bowe, Hong Xian, Travis Loux, Janet B McGill, Ziyad Al-Aly
BACKGROUND: Randomised clinical trials showed that compared with placebo, SGLT2 inhibitors and GLP-1 receptor agonists reduced risk of adverse cardiovascular events. The evidence base for the older antihyperglycaemic drug classes (DPP-4 inhibitors and sulfonylureas) is generally less well developed. Because most randomised trials evaluated one antihyperglycaemic medication versus placebo, a head-to-head comparative effectiveness analysis of the newer drug classes (SGLT2 inhibitors vs GLP-1 receptor agonists) or newer (SGLT2 inhibitors or GLP-1 receptor agonists) versus older (DPP-4 inhibitors or sulfonylureas) drug classes on risk of major adverse cardiovascular events (MACE) is not available...
July 24, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37499674/pragmatic-trials-a-step-forward-to-assess-cardiovascular-efficacy-of-new-glucose-lowering-agents
#18
JOURNAL ARTICLE
André J Scheen
No abstract text is available yet for this article.
July 24, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37475120/increased-cardiovascular-morbidity-and-mortality-in-patients-with-resistance-to-thyroid-hormone
#19
JOURNAL ARTICLE
Samuel Refetoff, Luca Persani, W Edward Visser
No abstract text is available yet for this article.
July 17, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/37475119/cardiovascular-morbidity-and-mortality-in-patients-in-wales-uk-with-resistance-to-thyroid-hormone-%C3%AE-rth%C3%AE-a-linked-record-cohort-study
#20
JOURNAL ARTICLE
Onyebuchi E Okosieme, Danyal Usman, Peter N Taylor, Colin M Dayan, Greta Lyons, Carla Moran, Krishna Chatterjee, Dafydd Aled Rees
BACKGROUND: Individuals with resistance to thyroid hormone owing to mutations in the thyroid hormone receptor β gene (RTHβ) exhibit impaired tissue sensitivity to thyroid hormones, but retain sensitivity in cardiac tissue. Long-term health and survival outcomes in this rare disorder have not been evaluated. We investigated all-cause mortality and cardiovascular event risk in a cohort of patients with RTHβ, followed-up in UK endocrine clinics. METHODS: In a retrospective cohort design, we linked genetically confirmed patients with RTHβ and age-matched and sex-matched population controls to outcomes in datasets within the Welsh Secure Anonymised Information Linkage (SAIL) Databank...
July 17, 2023: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.